Analysts expect Alexandria Real Estate Equities to report a 3.8% year-over-year decline in fourth-quarter revenues, projecting approximately $492 million versus $511 million a year earlier. The consensus adjusted funds from operations (FFO) estimate stands at $2.07 per diluted share, down from $2.15 in Q4 2024. Pressure on occupancy in the company’s life sciences portfolio—where vacancy rose to an estimated 7.1% at quarter end, compared with 5.4% in September—has weighed on lease renewals and tenant rollovers, contributing to the revenue shortfall and lower FFO expectations.

Occupancy in Alexandria’s core life sciences campuses is forecast to average 92.9% for the quarter, versus 94.3% in Q4 2024. Management commentary is likely to highlight challenges in backfilling space vacated by biotech tenants reducing lab footprints, particularly in the Bay Area and Boston markets. However, lease renewal spreads remain positive, with signed renewals on roughly 1.2 million square feet achieving an average rent increase of 4.2%, up from 3.5% a year ago, potentially indicating stabilization in rental rates.

As of December 31, Alexandria’s net debt to adjusted EBITDA ratio was estimated at 5.1x, modestly higher than the 4.9x reported three months earlier. The company maintained approximately $1.1 billion of undrawn revolver capacity and closed on two unsecured bond offerings totaling $550 million at average coupon rates near 5.1%. These financings, combined with expected operating cash flow of about $320 million for the quarter, should support capital deployment for new developments while preserving liquidity cushion.

While Alexandria has not provided formal full-year 2026 guidance, management commentary will be scrutinized for signs of a recovery in leasing activity and any adjustments to development starts. Investors will look for commentary on pre-leasing levels for projects scheduled to deliver in late 2026—currently at roughly 35% of 1.8 million rentable square feet—and any outlook on growth in adjusted FFO per share. Given current headwinds, the key takeaway will be whether the company can leverage its market leadership in life sciences real estate to arrest occupancy declines and resume modest FFO growth in the back half of the year.